Welcome to the e-CCO Library!

P435 Real-world clinical outcomes after elective discontinuation of first-use biologics in IBD patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

U.N. Shivaji1, A. Bazarova2, T. Critchlow3, O.M. Nardone4, S.C. Smith4, M. Love3, J. Davis3, S. Ghosh1, M. Iacucci1

Created: Thursday, 30 January 2020, 10:12 AM
P435: Effectiveness of therapeutic drug monitoring of infliximab and adalimumab in inflammatory bowel disease patients. Systematic review and meta-analysis
Year: 2018
Source: ECCO '18 Vienna
Authors:

P. Petryszyn*, L. Dybalski, K. Gola

Created: Thursday, 21 February 2019, 9:14 AM
P435: High rate of vitamin deficiencies in patients after total proctocolectomy and pouch surgery- results from a prospective cohort
Year: 2022
Source: ECCO'22
Authors: Elial-Fatal, S.(1);Pfeffer-Gik, T.(1,2);Raykhel, B.(1);Friedenberg, A.(1);Margolis, L.(1);Barkan, R.(1);Ollech, J.(1,2);Yanai, H.(1,2);Wasserberg, N.(2,3);White, I.(2,3);Dotan, I.(1,2);Godny, L.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
P435: Liver injury associated with anti-tumour necrosis factor therapy in paediatric irritable bowel disease patients
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Ricciuto*, B. M. Kamath, T. Walters, P. Church, S. C. Ling, K. Frost, A. Griffiths

Created: Friday, 22 February 2019, 9:49 AM
P435: Rapidity of symptomatic and inflammatory biomarker improvements following upadacitinib induction treatment: data from the U-ACHIEVE study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. D’Haens*1, E. V. Loftus Jr2, P. D. R. Higgins3, J. Panes4, R. Panaccione5, W. Zhou6, F. Cataldi6, W-J. Lee6, B. Huang6, W. Xie6, S. Vermeire7

Created: Friday, 22 February 2019, 9:41 AM
P435: The impact of perianal fistula in Crohn’s disease on quality of life: results of a patient survey conducted in Europe
Year: 2021
Source: ECCO'21 Virtual
Authors: Spinelli, A.(1,2);Yanai, H.(3);Lönnfors, S.(4);Girardi, P.(5);Milicevic, S.(6);Carvello, M.(1);Maroli, A.(1);Avedano , L.(4);
Created: Wednesday, 2 June 2021, 4:12 PM
P435: The mean corpuscular volume flow – prognostic value for inflammatory bowel disease under thiopurine treatment
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Roseira J.*1, Tavares de Sousa H.1, Marreiros A.2, Queiros P.1, Vaz A.M.1, Gago T.1, Contente L.1, Guerreiro H.1

Created: Wednesday, 20 February 2019, 10:36 AM
P436 Evaluation of targeted vitamin D supplementation regimen in postoperative patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. LI, L. Zheng, D. Yao, Z. Zhou, B. Liu, Y. Huang, Y. Duan

Created: Thursday, 30 January 2020, 10:12 AM
P436: Adalimumab dose escalation is effective and well tolerated in Crohn’s disease patients with secondary loss of response to adalimumab
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

N. Duveau*, M. Nachury, M. Boualit, R. Gerard, J. Branche, V. Maunoury, P. Desreumaux, B. Pariente

Created: Friday, 22 February 2019, 9:49 AM
P436: Darvadstrocel treatment outcomes in Crohn’s disease patients with complex perianal fistulas: the role of TNFi co-treatment in ADMIRE CD
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Panés*1, D. García-Olmo2, D. Lindner3, I. Tagarro García4, C. Agboton3

Created: Friday, 22 February 2019, 9:41 AM
P436: Efficacy and safety of biosimilars of anti-TNF-a in paediatric-onset Inflammatory Bowel Disease: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
Year: 2022
Source: ECCO'22
Authors: Dipasquale, V.(1);Pellegrino, S.(1);Cucinotta, U.(1);Citrano, M.(2);Graziano, F.(2);Cappello, M.(3);Busacca, A.(3);Orlando, A.(4);Accomando, S.(5);Romano, C.(1);
Created: Friday, 11 February 2022, 3:52 PM
P436: Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn's disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trial
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Schreiber, S.W.(1)*;Lee, S.(2);van der Woude , C.J.(3);Marín-Jiménez , I.(4);Wolf, D.(5);Schnoy, E.(6);Salzberg , B.(7);Busse , C.(8);Nazar, M.(9);Langholff, W.(10);Borghorst, S.(11);Gasink, C.(8);Baker, T.(12);Godwin, B.(8);Feagan, B.(13);
Created: Friday, 14 July 2023, 11:05 AM
P436: Ileal pouch-anal anastomosis with fluorescence angiography: Initial experience and potential application
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Spinelli1*, P.G. Kotze2, M. Carvello1, F. Di Candido1, N. Buchs3, F. Ris4

Created: Thursday, 21 February 2019, 9:14 AM
P436: Secondary loss of response to anti-TNF in inflammatory bowel diseases. Therapeutic drug monitoring. Utility in clinical practice
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Jimenez M.*1, Sierra-Ausin M.1, Cano N.1, Suarez P.1, Fernandez-Gundin M.1, Saez-Villafañe M.2, Monteserin L.1, Molina G.1, Reyes N.1, Viso D.1, Jorquera F.1

Created: Wednesday, 20 February 2019, 10:36 AM
P436: SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501
Year: 2021
Source: ECCO'21 Virtual
Authors: Macaluso, F.(1);Cappello, M.(2);Busacca, A.(2);Fries, W.(3);Viola, A.(3);Costantino, G.(3);Magnano, A.(4);Vinci, E.(4);Ferracane, C.(4);Privitera, A.C.(5);Piccillo, G.(5);Belluardo, N.(6);Giangreco, E.(6);Romano, C.(7);Citrano, M.(8);Graziano, F.(8);Garufi, S.(9);Bertolami, C.(10);Scrivo, B.(1);Renna, S.(1);Casà, A.(1);Rizzuto, G.(1);Ventimiglia, M.(1);Orlando, A.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P437 Anti-TNF α antibodies in patients with inflammatory bowel disease naive to anti-TNF therapy treated with biosimilar infliximab (CT-P13): a prospective single-centre real-life study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Filip1, A. Pękala1, S. Jarmakiewicz-Czaja2

Created: Thursday, 30 January 2020, 10:12 AM
P437: Autologous hematopoietic stem cell transplantation for refractory Crohn's disease: predictive factors of relapse
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Lόpez García A.*1, Rovira M.2, Jauregui Amezaga A.1, Marin P.3, Barastegui R.1, Salas A.1, Feu F.1, Elizalde J.1, Fernández-Avilés F.2, Martínez C.4, Gutierrez G.2, Rosiñol L.2, Carreras E.2, Urbano A.2, Lozano M.3, Cid J.3, Suárez-Lledό M.2, Masamunt M.C.1, Comas D.1, Giner A.1, Gallego M.1, Alfaro I.1, Ordás I.1, Panés J.1, Ricart E.1

Created: Wednesday, 20 February 2019, 10:36 AM
P437: Confidence, acceptance, and friendship: the 3 winners at Camp Purple Live 2015
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. McCombie*1, 2, R. Gearry3, R. Lopez4, S. Lönnfors5, A. Day4

Created: Friday, 22 February 2019, 9:49 AM
P437: Early therapeutic drug monitoring of Adalimumab, but not HLADQ*A1 determination, predicts inflammatory bowel disease outcome .
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Carrillo Palau, M.(1)*;Alonso-Abreu, I.(1);Morant, A.(1);Vera, B.(1);Vela , M.(2);Ramos, L.(1);Franco, A.(3);Reygosa, C.(1);Barrios, Y.(3);Medina Chico, J.S.(1);Globio, V.(4);Hernández-Perez, A.(1);Jiménez, A.(5);Hernández-Guerra, M.(1);
Created: Friday, 14 July 2023, 11:05 AM